<code id='586E1D6514'></code><style id='586E1D6514'></style>
    • <acronym id='586E1D6514'></acronym>
      <center id='586E1D6514'><center id='586E1D6514'><tfoot id='586E1D6514'></tfoot></center><abbr id='586E1D6514'><dir id='586E1D6514'><tfoot id='586E1D6514'></tfoot><noframes id='586E1D6514'>

    • <optgroup id='586E1D6514'><strike id='586E1D6514'><sup id='586E1D6514'></sup></strike><code id='586E1D6514'></code></optgroup>
        1. <b id='586E1D6514'><label id='586E1D6514'><select id='586E1D6514'><dt id='586E1D6514'><span id='586E1D6514'></span></dt></select></label></b><u id='586E1D6514'></u>
          <i id='586E1D6514'><strike id='586E1D6514'><tt id='586E1D6514'><pre id='586E1D6514'></pre></tt></strike></i>

          Home / knowledge / focus

          focus


          focus

          author:focus    Page View:863
          Hiram Secrist (left), who has Duchenne muscular dystrophy, with his mother, Kristen Secrist (center), and his grandmother, Terrie Jordan. Courtesy Secrist family

          In mid-July, Kristen Secrist hopped on a call with her 5-year-old son’s doctor, who had urgent news: The first gene therapy had been approved for Duchenne muscular dystrophy. Her son, Hiram, would be a perfect candidate — if, she added, they could get him dosed in time.

          The treatment was approved only for 4- and 5-year-olds. Hiram turned 6 in three weeks. 

          advertisement

          “Oh, crap,” Secrist said to herself.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In